Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: $COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Collegium Pharmaceutical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Collegium Pharmaceutical's position in the market.
Collegium Pharmaceutical, Inc. reported strong Q1 2024 financial results, including a net revenue of $144.9 million, record Belbuca® revenue of $50.7 million, and GAAP net income of $27.7 million. The company achieved a 5% increase in Adjusted EBITDA, authorized a $35.0 million share repurchase program, and reaffirmed its full-year 2024 guidance. Collegium also announced an authorized generic agreement with Hikma and a leadership transition. Financially, the company showed stable product revenues, reduced GAAP operating expenses, and increased cash reserves.
Collegium Pharmaceutical, Inc. announces CEO transition as Joe Ciaffoni steps down as President and CEO, effective May 24, 2024. Michael Heffernan will serve as Interim President and CEO until a successor is appointed. The Board has initiated the search for a new CEO. Collegium remains financially strong and on track to achieve its 2024 financial guidance.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has announced an authorized generic agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER, bolstering the value of the Nucynta Franchise through 2025 and beyond. Collegium will manufacture and supply Hikma with authorized generic products, with Hikma having exclusive rights to sell them in the U.S. Collegium will receive a share of net profits based on the number of generic entrants.